Immunome (IMNM) Stock Forecast & Price Target

Immunome is viewed favorably because it combines a near-term commercial opportunity in varegacestat with a multi-asset oncology pipeline that could expand the company beyond a single-program story, including positive topline Phase 3 RINGSIDE results in desmoid tumors and a stated April 28, 2027 PDUFA that supports a 2027 U.S. launch and about $66M in first-year revenue estimates. Its ADC strategy is also compelling because IM-1021, IM-3050, IM-1617, IM-1340, and IM-1335 create multiple shots on goal in areas where target biology, payload engineering, and bystander effects can still drive meaningful efficacy even when antigen density is imperfect, while upcoming initial lymphoma data in 2H26 and additional INDs in 2026 provide several identifiable catalysts. The positive outlook is further reinforced by the view that ROR1 remains a plausible oncology target despite debate over density and biomarker gating, and by a “Seagen 2.0” thesis that positions Immunome as a platform with enough clinical and commercial optionality to support sustained fundamental upside.

Immunome is viewed negatively because, despite a promising lead asset in varegacestat, much of the broader pipeline remains early, with IM-1021 only in Phase 1, IM-1617 and IM-3050 just dosing first patients, and IM-1340 and IM-1335 still awaiting IND submissions, leaving limited near-term fundamental diversification. The core ROR1 thesis is also uncertain because bystander payload activity may reflect heterogeneity more than true target-density biology, clinical benefit in DLBCL may be insufficient versus bispecific antibodies and CAR-T, and there are no credible biomarkers to guide patient selection, which weakens confidence in durable differentiation. While Immunome ended 2Q26 with $520MM in cash and expects runway into 2028, that balance sheet support does not offset the commercial and clinical concentration risk around a single late-stage asset or guarantee that the current valuation fully reflects the execution, competitive, and regulatory hurdles across its still-unproven ADC platform.